BAGSVAERD, DENMARK--(Marketwire - August 24, 2009) - Novo Nordisk A/S - Share repurchase programme
On 7 August 2009 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission’s regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.
Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 2.4 billion in the period from 10 August 2009 to 18 December 2009.
Since the announcement as of 17 August 2009, the following transactions have been made under the programme:
Number of shares Average Transaction purchase price value, DKK Accumulated, last announcement 375,000 116,994,750 17 August 2009 75,000 317.1800 23,788,500 18 August 2009 75,000 313.8000 23,535,000 19 August 2009 75,000 310.9590 23,321,925 20 August 2009 75,000 314.7100 23,603,250 21 August 2009 75,000 317.6400 23,823,000 Accumulated under the programme 750,000 235,066,425
Transactions related to Novo Nordisk’s incentive programmes have resulted in a net sale by Novo Nordisk of 41,650 B shares in the period from 17 August 2009 to 21 August 2009. The shares in these transactions were not part of the Safe Harbour repurchase programme.
With the transactions stated above, Novo Nordisk owns a total of 25,586,808 treasury shares, corresponding to 4.1% of the share capital. The total amount of shares in the company is 620,000,000 including treasury shares.
Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 27,900 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk’s B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol ‘NVO’. For more information, visit novonordisk.com.
Further information: Media: Investors: Outside North America: Outside North America: Elin K Hansen Mads Veggerby Lausten Tel: (+45) 4442 3450 Tel: (+45) 4443 7919 ekh@novonordisk.com mlau@novonordisk.com Kasper Roseeuw Poulsen Tel: (+45) 4442 4471 krop@novonordisk.com In North America: In North America: Sean Clements Hans Rommer Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937 secl@novonordisk.com hrmm@novonordisk.com Company Announcement no 51 / 2009
This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Copyright © Hugin AS 2009. All rights reserved.
